

Arrow Pharma Pte Limited
BALANCE SHEET AS AT Mar 31, 2016

	<u>Schedule</u>	<u>Mar-16</u> <u>USD</u>
A . EQUITY AND LIABILITIES		
1. Shareholders' funds		
a) Share capital	1	72,625
b) Reserves and Surplus	2	(360,205)
		(287,580)
2. Share application money pending allotment		620,974
3. Minority Interest		-
4. Non Current Liabilities		
a) Long Term borrowing	3	-
b) Deferred Tax liabilities (Net)		-
c) Other Long Term Liabilities	4	-
d) Long Term Provisions	5	-
		-
5. Current Liabilities		
a) Short Term borrowing	6	-
b) Trade Payables	7	4,962
c) Other Current Liabilities	8	201,556
d) Short Term Provisions	9	-
		-
Total		539,912
B . ASSETS		
1 . NON CURRENT ASSETS		
a. Fixed Assets		
i) Tangible Assets	10	1,668
ii) Intangible Assets		-
iii) Capital Work in Progress		-
iv) Intangible Assets Under Development		-
v) Fixed Assets held for Sale\		-
		1,668
b. Non Current Investments	11	436,875
c. Deferred Tax Assets (Net)	12	-
d. Long Term Loans and Advances	13	-
e. Other Non Current Assets	14	-
		436,875
2 . CURRENT ASSETS		
a Current investments	15	-
b Inventories	16	-
c Trade receivables	17	-
d Cash and cash equivalents	18	29,099
e Short-term loans and advances	19	72,271
f Other current assets	20	-
		101,369
Total		539,912

Arrow Pharma Pte Limited
STATEMENT OF PROFIT & LOSS
FOR THE PERIOD ENDED Mar 31, 2015

	<u>Schedule</u>	<u>For the period ended Mar-16 USD</u>
A . CONTINUING OPERATIONS		
1. Revenue from Operations (Gross)	21	-
Less: Excise Duty	21	-
Revenue from Operations Net		-
2. Expenses		
a. Cost of Materials consumed	22.1	-
b. Purchases of Stock in Trade	22.2	
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	22.3	-
d. Employee benefits expense	23	179,528
f. Other expenses	24	178,760
Total Expenses		358,288
3. Earnings before exceptional items, extraordinary items, interest, tax, depreciation and amortisation (EBITDA) (1 - 2)		(358,288)
4. Finance Cost	25	1,795
5. Depreciation and amortisation expense	10	121
6. Other Income	26	-
7. Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4- 5 + 6)		(360,205)
8. Exceptional Items		-
9. Profit / (Loss) before tax (9 + 10)		(360,205)
12. Tax Expense		
a Current tax expense for current year		-
b (Less): MAT credit (where applicable)		-
c Current tax expense relating to prior years		-
d Net current tax expense		-
e Deferred tax		-
		-
13. Profit / (Loss) from continuing operations (11 + 12)		(360,205)

Arrow Pharma Pte Limited

Schedules forming part of the Consolidated Balance Sheet

Mar-16
USD

SCHEDULE 1
SHARE CAPITAL

1. Authorised
a) Equity

b) Preference

_____ -

2. Issued, subscribed and paid-up

a) Equity

72,625

a) Preference

-

Total

_____ **72,625**

=====

Arrow Pharma Pte Limited**Schedules forming part of the Consolidated Balance Sheet****Mar-16**
USD**SCHEDULE 2****RESERVES AND SURPLUS****1. General Reserve**

Opening Balance	-
Add: Transfer from Profit and loss account	-
Closing Balance	-

2. Capital Reserve

Opening Balance	-
Add: Transfer from Profit and loss account	-
Closing Balance	-

3. Securities Premium Account

Opening Balance	-
Add: Premium on Shares issued during the year	-
Less : Utilisation during the Year	-
Closing Balance	-

4. Profit & Loss Account

Opening Balance	-
Add: Profit for the Year	(360,205)
Less:	
Proposed Dividend Equity Share Holders	
Proposed Dividend Preference Share Holders	
Tax on dividend	
Transferred to :	
General Reserve	
Capital Redemption reserve	
Debenture Redemption reserve	
Other reserves (Details)	
Closing Balance	(360,205)

5. Other Reserves (Please Specify and Link it from TB)**6. Exchange reserve (on consolidation)**

-

Total**(360,205)****NON CURRENT LIABILITIES****Long Term Borrowings 3****Secured**

a) Term Loans from Banks	-
b) Term Loans From Financial institutions	-
c) Loans and advances from related parties	
d) Deposits	
e) Long-term maturities of finance lease obligations	
f) Other loans and advances	-

Arrow Pharma Pte Limited**Schedules forming part of the Consolidated Balance Sheet****Mar-16**
USD**Short Term Borrowings 6****Secured**

a) Loans repayable on demand from Banks	-
b) Loans repayable on demand from Financial Institutions	-
c) Loans and advances from related parties	-
d) Deposits	-
f) Other loans and advances	-
	<hr/>
	-
	<hr/>

Unsecured

a) Loans repayable on demand from Banks	-
b) Loans repayable on demand from Other parties	-
c) Loans and advances from related parties	-
d) Deposits	-
f) Other loans and advances	-
	<hr/>
	-
	<hr/>
	-
	<hr/>

Total**Trade Payables 7**

Acceptances	
Other than Acceptances	4,962
	<hr/>
	4,962
	<hr/>

Other Current Liabilities 8

(a) Current maturities of long-term debt	-
(b) Current maturities of finance lease obligations	-
(c) Interest accrued but not due on borrowings	-
(d) Interest accrued and due on borrowings	-
(e) Income received in advance (Unearned revenue)	-
(f) Unclaimed dividends	-
(g) Other payables	-
(i) Statutory remittances	-
(ii) Payables on purchase of fixed assets	-
(iii) Contractually reimbursable expenses	-
(iv) Interest accrued on trade payables	-
(v) Interest accrued on others	-
(vi) Trade / security deposits received	201,556
(vii) Advances from customers	-
(viii) Others (specify nature)	-
	<hr/>
	201,556
	<hr/>

Short Term Provisions 9

(a) Provision for employee benefits:	
(i) Provision for bonus	-
(ii) Provision for compensated absences	-
(iii) Provision for gratuity	-
(iv) Provision for post-employment medical benefits	-
(v) Provision for other defined benefit plans	-
(vi) Provision for other employee benefits (give details)	-

Arrow Pharma Pte Limited**Schedules forming part of the Consolidated Balance Sheet****Mar-16**
USD

(b) Provision - Others:	
(i) Provision for tax (net of advance tax ` ____ (As at 31 March, 20X1 ` ____)	-
(ii) Provision for premium payable on redemption of bonds	
(iii) Provision for estimated loss on derivatives	
(iv) Provision for warranty	
(v) Provision for estimated losses on onerous contracts	
(vi) Provision for other contingencies	
(vii) Provision for proposed equity dividend	-
(viii) Provision for proposed preference dividend	-
(ix) Provision for tax on proposed dividends	-
(x) Provision - others (give details)	-
	<hr/>
	<hr/>

1 . NON CURRENT ASSETS**Long Term Loans and Advances 13**

(a) Capital advances	
Secured, considered good	
Unsecured, considered good	-
Doubtful	
Less: Provision for doubtful advances	<hr/>
	<hr/>
(b) Security deposits	
Secured, considered good	
Unsecured, considered good	-
Doubtful	
Less: Provision for doubtful deposits	<hr/>
	<hr/>
(c) Loans and advances to related parties	
Secured, considered good	
Unsecured, considered good	
Doubtful	
Less: Provision for doubtful loans and advances	<hr/>
	<hr/>
(d) Loans and advances to employees	
Secured, considered good	
Unsecured, considered good	-
Doubtful	
Less: Provision for doubtful loans and advances	<hr/>
	<hr/>
(e) Prepaid expenses - Unsecured, considered good	-
(f) Advance income tax (net of provisions)	-

Arrow Pharma Pte Limited**Schedules forming part of the Consolidated Balance Sheet****Mar-16**
USD

(h) Balances with government authorities	
Unsecured, considered good	
(i) CENVAT credit receivable	-
(ii) VAT credit receivable	-
(iii) Service Tax credit receivable	-
(iv) Others	-
(i) Other loans and advances (specify nature)	
Secured, considered good	-
Unsecured, considered good	
Doubtful	
Less: Provision for other doubtful loans and advances	
	<hr/>
	-
	<hr/>
Total	-

Other Non Current Assets 14

(a) Long-term trade receivables	
Secured, considered good	
Unsecured, considered good	
Doubtful	-
Less: Provision for doubtful trade receivables	
	<hr/>
	-
	<hr/>
(b) Unamortised expenses	
(i) Ancillary borrowing costs	
(ii) Share issue expenses (where applicable)	
(iii) Discount on shares (where applicable)	
(c) Accruals	
(i) Interest accrued on deposits	
(ii) Interest accrued on investments	-
(iii) Interest accrued on trade receivables	
(d) Others	
(i) Insurance claims	
(ii) Receivables on sale of fixed assets	
(iii) Contractually reimbursable expenses	
(iv) Others (specify nature)	
	<hr/>
	-
	<hr/>

2 . CURRENT ASSETS**Inventories 16**

(a) Raw materials	-
Goods-in-transit	-
(b) Work-in-progress	-
Goods-in-transit	

Arrow Pharma Pte Limited**Schedules forming part of the Consolidated Balance Sheet****Mar-16
USD**

(c) Finished goods (other than those acquired for trading)	-
Goods-in-transit	-
(d) Stock-in-trade (acquired for trading)	-
Goods-in-transit	-
(e) Stores and spares	-
Goods-in-transit	-
(f) Loose tools	-
Goods-in-transit	-
(g) Others (Specify nature)	-
Goods-in-transit	-
	<hr/>
	-
	<hr/>

Trade Receivables 17

Trade receivables outstanding for a period exceeding six months from the date they were due for payment	
Secured, considered good	
Unsecured, considered good	-
Doubtful	-
Less: Provision for doubtful trade receivables	-
	<hr/>
	-
	<hr/>
Other Trade receivables	
Secured, considered good	
Unsecured, considered good	-
Doubtful	-
Less: Provision for doubtful trade receivables	-
	<hr/>
	-
	<hr/>
Total	-

Cash and Bank Balances 18**Cash and Cash Equivalents**

(a) Cash on hand	12,813
(b) Cheques, drafts on hand	
(c) Balances with banks	
(i) In current accounts	16,286
(ii) In EEFC accounts	
(iii) In deposit accounts	-
(iv) In earmarked accounts	
- Unpaid dividend accounts	-
- Unpaid matured deposits	
- Unpaid matured debentures	
- Share application money received for allotment of securities and due for refund	
- Other earmarked accounts	-
(d) Others (specify nature)	

Bank Balances

- Balances held as margin money or security against borrowings, guarantees and other commi	-
--	---

Total	<hr/>
	29,099
	<hr/>

Arrow Pharma Pte Limited**Schedules forming part of the Consolidated Balance Sheet****Mar-16**
USD**Short Term Loans and Advances 19**

(a) Security deposits	
Secured, considered good	
Unsecured, considered good	-
Doubtful	
Less: Provision for doubtful deposits	
	<hr/>
	-
(b) Loans and advances to related parties	
Secured, considered good	
Unsecured, considered good	72,271
Doubtful	
Less: Provision for doubtful loans and advances	
	<hr/>
	72,271
(d) Loans and advances to employees	
Secured, considered good	
Unsecured, considered good	-
Doubtful	
Less: Provision for doubtful loans and advances	
	<hr/>
	-
(e) Prepaid expenses - Unsecured, considered good	-
(f) Advance income tax (net of provisions)	-
(h) Balances with government authorities	
Unsecured, considered good	
(i) CENVAT credit receivable	-
(ii) VAT credit receivable	-
(iii) Service Tax credit receivable	-
(iv) Others	-
(i) Other loans and advances (specify nature)	
Secured, considered good	
Unsecured, considered good	-
Doubtful	
Less: Provision for other doubtful loans and advances	
	<hr/>
	-
Total	<hr/>
	72,271

Other Current Assets 20

(a) Unbilled Revenue	-
(b) Unamortised expenses	
(i) Ancillary borrowing costs	
(ii) Share issue expenses (where applicable)	
(iii) Discount on shares (where applicable)	
(iv) Other Deferred Expenses	-
(c) Accruals	
(i) Interest accrued but not received /Interest receivable	-
(ii) Interest accrued on investments	
(iii) Interest accrued on trade receivables	
(d) Others	
(i) Insurance claims	
(ii) Receivables on sale of fixed assets	
(iii) Contractually reimbursable expenses	
(iv) Others (specify nature)	
	<hr/>
	-

Schedules forming part of the Consolidated Balance Sheet

Note 10

Fixed Assets & Intangible Assets

Particulars	GROSS BLOCK				DEPRECIATION/AMORTISATION				NET BLOCK		
	As on Apr 01, 2015	Consolidation adjustment	Additions During the year	Deletions During the year	As on Mar 31, 2016	Upto Mar 31, 2015	For the Year	Withdrawn on Deletions / Adjustments	Upto Mar 31, 2016	As on Mar 31, 2016	As on Mar 31, 2015
Tangible Assets:											
Freehold Land					-				-	-	-
Leasehold Land					-				-	-	-
Buildings					-				-	-	-
Furniture & Fixtures	-		563.00		563.00	-	18.57		18.57	544.43	-
Office Equipments & Computers	-		1,226.00		1,226.00	-	102.92		102.92	1,123.08	-
Plant & Machinery					-				-	-	-
Motor Vehicles					-				-	-	-
Intangible Assets:											
Registrations & Brands					-				-	-	-
Software Licences			-	-	-				-	-	-
Total	-	-	1,789.00	-	1,789.00	-	121.49	-	121.49	1,667.51	-
<i>Previous year</i>					-				-	-	-
Capital work in Progress										-	-
Intangible assets under development										-	-
Grand Total										1,667.51	-

Arrow Pharma Pte Limited

Schedules forming part of the Consolidated Profit & Loss account

For the period ended
March 31, 2016
USD

Revenue From Operations 21

Sale of products	-
Sale of Services	-
Other Operating Revenue	-
Less: Excise duty	-
Revenue from Operations	-

Other Income 26

Exchange fluctuation gain (net)	-
Dividend Income	-
Net gain on sale of Investments	-
Profit on Sale / Disposal of assets	-
Interest Income	-
Other Non Operating Income	-

Total **-**

Cost Of Materials Consumed 22

Cost of Materials Consumed	
Opening stock	-
Add: Purchases	-
Less: Closing stock	-

Total **-**

INCREASE / (DECREASE) IN STOCK

i) Opening stock	
Work in process	-
Stock In Trade	-
Finished goods	-

iii) Closing stock	
Work in process	-
Stock In Trade	-
Finished goods	-

Total **-**

Arrow Pharma Pte Limited

Schedules forming part of the Consolidated Profit & Loss account

For the period ended
March 31, 2016
USD

Employee Benefit Expenses 23

Salaries and wages	179,528
Contribution to provident and other funds	-
Expense on employee stock option (ESOP) scheme	-
Staff welfare expenses	-
Total	<u>179,528</u>

Other Expenses 24

Power, fuel & water	344
Consumables	-
R & D Expense	-
Conversion & Processing charges	110,000
Excise duty paid	-
Freight & forwarding	-
Rent	7,000
Rates & taxes	15,853
Communication charges	1,114
Repairs & maintenance	-
- Buildings	-
- Machinery	-
- Others	822
Insurance	-
Travelling & conveyance	24,832
Advertisement & Selling expenses	204
Commission on sales	-
Legal and Professional fees	11,694
Other expenses	6,897
Cost of product rights transferred	-
Provision for doubtful debts	-
Exchange fluctuation Loss	-
Miscellaneous expense	-
Total	<u>178,760</u>

Finance Cost 25

Bank charges & commission	1,795
Interest on Borrowings	-
Interest on Trade Payables	-
Other Interest Cost	-
Other Borrowing Cost	-
Total	<u>1,795</u>